HCPCS Code Applications and Approvals: October 2022
Quarterly archive · CMS Level II HCPCS14 coding decisions from the Second Quarter 2022 CMS cycle
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Second Quarter 2022 coding cycle, which took effect October 1, 2022.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
October 2022
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9602 | Fluorodopa F 18 Fluorodopa f-18, diagnostic, per millicurie | The Feinstein Institute for Medical Research Intravenous | — | Establish | |
| A9607 | PLUVICTO Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie | Advanced Accelerator Applications, a Novartis company Intravenous | — | Establish | |
| A9800 | LOCAMETZ Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie | Advanced Accelerator Applications, a Novartis company Intravenous | — | Establish | |
| C9095 | KIMMTRAK Injection, tebentafusp-tebn, 1 microgram | Immunocore Commercial LLC Intravenous | Replaced byJ9274 | Discontinue | |
| C9096 | Releuko Biosimilar Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Amneal Pharmaceutical, Inc | Replaced byQ5125 | Discontinue | |
| C9097 | VABYSMO Injection, faricimab-svoa, 0.1 mg | Genentech Inc. Intravitreal | Replaced byJ2777 | Discontinue | |
| C9098 | CARVYKTITM Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | — Intravenous | Replaced byQ2056 | Discontinue | |
| J1302 | ENJAYMO Injection, sutimlimab-jome, 10 mg | Sanofi | — | Establish | |
| J1932 | Lanreotide Injection, lanreotide, (cipla), 1 mg | Cipla USA, Inc. Subcutaneous | — | Establish | |
| J2777 | VABYSMO Injection, faricimab-svoa, 0.1 mg | Genentech Inc. Intravitreal | ReplacesC9097 | Establish | |
| J9274 | KIMMTRAK Injection, tebentafusp-tebn, 1 microgram | Immunocore Commercial LLC Intravenous | ReplacesC9095 | Establish | |
| J9298 | OPDUALAG Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | Bristol Myers Squibb Intravenous | — | Establish | |
| Q2056 | CARVYKTITM Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | — Intravenous | ReplacesC9098 | Establish | |
| Q5125 | Releuko Biosimilar Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Amneal Pharmaceutical, Inc | ReplacesC9096 | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Second Quarter 2022 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
